[Evaluation of the effectiveness and tolerability of MED 15 vs. piroxicam in patients with acute epicondylitis].
In this trial we studied 30 patients with acute epicondylitis: 15 were treated with Med 15, a new non-steroidal anti-inflammatory drug, and 15 with piroxicam. Med 15 was administered orally for 15 days: the first 2 days 2 tablets daily (1.200 mg) and the following 13 days 1 tablet daily (600 mg). Piroxicam was administered 2 tablets the first 2 days and 1 tablet daily the following 13 days. It was demonstrated that the new compound is significantly more active and better tolerated than the reference drug.
Meloni
P
P
USL N. 20, P.O. Ospedale marino Sezione Autonoma, Cagliari Chirurgia della Mano.
Demuro
G
G
Cara
L
L
Garau
D
D
Uras
G
G
Suddu
L
L
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010894:Piroxicam / Q000494:pharmacology / Q000627:therapeutic use*; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use*; D013716:Tennis Elbow / Q000188:drug therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011758:Pyrroles; C065762:ST 679; D010894:Piroxicam; D005998:Glycine
Valutazione dell'efficacia e tollerabilità di MED 15 verso piroxicam in pazienti affetti da epicondilite acuta.